Kourides I A, Weintraub B D, Rosen S W, Ridgway E C, Kliman B, Maloof F
J Clin Endocrinol Metab. 1976 Jul;43(1):97-106. doi: 10.1210/jcem-43-1-97.
In 60 patients with pituitary adenomas, the serum concentration of the alpha subunit of the glycoprotein hormones (serum alpha) was measured by a sensitive and specific radioimmunoassay. Five patients had markedly elevated serum alpha prior to therapy (range 14.5-23.0 ng/ml). These 5 patients included 2 hyperthyroid men with inappropriately high serum thyrotropin, one of whom also had acromegaly, a man with hyperprolactinemia and elevated cerebrospinal fluid alpha, a postmenopausal woman with low serum gonadotropins and hyperprolactinemia, and a man with central hypothyroidism and hypogonadism. Three of the 5 were restudied after therapy; serum alpha in these three decreased from19.5 to 10.6, 23.0 to 2.0, and 17.0 to 12.0 ng/ml. Alpha in these 3 patinets' serum eluted similarly to normal pituitary alpha by gel chromatography. The other 55 patinets, including twenty with acromegaly, fifteen with galactorrhea, and two with Nelson's syndrome, had serum alpha.less than 0.5-5.0 ng/ml. In addition, 22 patients with "empty sella" syndrome (no pituitary tumor) had alpha less than 0.5-5.0 ng/ml. Normal men and premenopausal women had serum alpha concentrations of less than 0.5-2.5 ng/ml; normal postmenopausal women, 1.0-7.0 ng/ml; and patients with primary hypothyroidism, 0.7-9.0 ng/ml. The decreased alpha response to thyrotropin and luteinizing hormone-releasing hormones (TRH and LHRH) implied a relative autonomy of pituitary tumor alpha secretion; the mean alpha increment in the 5 patients with elevated serum alpha was 15% after TRH administration and 10% after LHRH. Normal individuals and patients with primary hypothyroidism demonstrated greater mean per cent alpha increments after TRH or LHRH. In certain patients with an enlarged sella turcica, an elevated serum alpha with little or no increase in secretion after TRH and LHRH may suggest the presence of pituitary tumor.
对60例垂体腺瘤患者,采用灵敏且特异的放射免疫分析法测定了糖蛋白激素α亚基的血清浓度(血清α)。5例患者在治疗前血清α显著升高(范围为14.5 - 23.0 ng/ml)。这5例患者包括2例患有甲状腺功能亢进且促甲状腺素水平异常升高的男性,其中1例还患有肢端肥大症;1例患有高催乳素血症且脑脊液α升高的男性;1例绝经后女性,血清促性腺激素水平低且伴有高催乳素血症;以及1例患有中枢性甲状腺功能减退和性腺功能减退的男性。5例中的3例在治疗后再次进行检测;这3例患者的血清α从19.5降至10.6、从23.0降至2.0以及从17.0降至12.0 ng/ml。通过凝胶色谱法,这3例患者血清中的α洗脱情况与正常垂体α相似。其他55例患者,包括20例肢端肥大症患者、15例溢乳症患者以及2例尼尔森综合征患者,血清α低于0.5 - 5.0 ng/ml。此外,22例患有“空蝶鞍”综合征(无垂体肿瘤)的患者血清α低于0.5 - 5.0 ng/ml。正常男性和绝经前女性血清α浓度低于0.5 - 2.5 ng/ml;正常绝经后女性为1.0 - 7.0 ng/ml;原发性甲状腺功能减退患者为0.7 - 9.0 ng/ml。对促甲状腺素和促黄体生成素释放激素(TRH和LHRH)的α反应降低意味着垂体肿瘤α分泌具有相对自主性;血清α升高的5例患者在给予TRH后α平均升高15%,给予LHRH后升高10%。正常个体和原发性甲状腺功能减退患者在给予TRH或LHRH后α平均升高百分比更高。在某些蝶鞍扩大的患者中,血清α升高且在给予TRH和LHRH后分泌很少或无增加,可能提示存在垂体肿瘤。